产品
编 号：F749127
产品类型
规格
价格
是否有货
1mg
询价
询价
结构图
CAS No: 2119595-80-9
产品详情
生物活性：
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).
体内研究：
Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG（NOD/SCID/γc-/）小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性。Animal Model:Female NSG mice infected with H929 cell lines
Dosage:0.1 μg (0.005 mg/kg), 0.5 μg (0.025 mg/kg), or 1 μg (0.05 mg/kg)
Administration:i.v., on days 0, 3, 5, 7, and 10
Result:Completely inhibited tumor growth at doses of 0.5 and 1 μg, while no inhibition of tumor growth was observed at a dose of 0.1 μg.
体外研究：
Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性，在 H929 细胞中的 EC50 值为 0.15 nM，在MM.1R 细胞系中为 0.06 nM，在 RPMI 8226 细胞系中为 0.45 nM。Teclistamab (0.01-1000 nM, 48 h) 能以剂量依赖方式结合 CD138 +人 BM 单核细胞，并诱导人 BM 单核细胞的细胞毒性。
Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM).
体内研究：
Teclistamab (i.v., 0.1-1 μg, once every 2 days) 在雌性 NSG（NOD/SCID/γc-/）小鼠 H929 细胞模型中具有大剂量的抗肿瘤活性。Animal Model:Female NSG mice infected with H929 cell lines
Dosage:0.1 μg (0.005 mg/kg), 0.5 μg (0.025 mg/kg), or 1 μg (0.05 mg/kg)
Administration:i.v., on days 0, 3, 5, 7, and 10
Result:Completely inhibited tumor growth at doses of 0.5 and 1 μg, while no inhibition of tumor growth was observed at a dose of 0.1 μg.
体外研究：
Teclistamab (0.01-1000 nM, 48 h) 可以诱导 T 细胞介导的细胞毒性，在 H929 细胞中的 EC50 值为 0.15 nM，在MM.1R 细胞系中为 0.06 nM，在 RPMI 8226 细胞系中为 0.45 nM。Teclistamab (0.01-1000 nM, 48 h) 能以剂量依赖方式结合 CD138 +人 BM 单核细胞，并诱导人 BM 单核细胞的细胞毒性。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备